Skip to content

Efficacy of Orthokine Eye Drops in the Treatment of Severe Refractory Dry Eye Disease

Pilot Study on the Safety and Efficacy of Orthokine Eye Drops in the Treatment of Severe Refractory Dry Eye Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130812014333N274
Enrollment
12
Registered
2026-01-24
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye syndrome. Dry eye syndrome

Interventions

Intervention 1: The intervention group will receive Orthokine drops, two drops in each eye, four times a day (every 6 hours), for 12 days, in addition to common and standard treatments (such as artifi

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Informed consent Age between 18 and 70 years old Diagnosis of severe dry eye by an ophthalmologist (based on clinical and paraclinical criteria)

Exclusion criteria

Exclusion criteria: Having active systemic diseases (such as lupus or uncontrolled Sjögren's syndrome) History of eye surgery in the past 6 months Taking medications that affect tear production History of response to standard treatments such as artificial tears, cyclosporine, or autologous serum

Design outcomes

Primary

MeasureTime frame
Severity of dry eye symptoms. Timepoint: On days zero, six, and twelve. Method of measurement: using Ocular Surface Disease Index.;Tear Production Rate. Timepoint: On days zero, six, and twelve. Method of measurement: Using the Schirmer test and tear break-up time test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Kamran Mansouri

Kermanshah University of Medical Sciences

kmansouri@kums.ac.ir+98 83 3427 4618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026